Bicycle Therapeutics plc (NASDAQ:BCYC) Receives $29.14 Average Target Price from Analysts

Shares of Bicycle Therapeutics plc (NASDAQ:BCYC - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the eight research firms that are presently covering the firm, Marketbeat Ratings reports. Two investment analysts have rated the stock with a hold rating and six have issued a buy rating on the company. The average 1-year target price among analysts that have covered the stock in the last year is $29.14.

A number of equities research analysts recently weighed in on the company. Stephens restated an "equal weight" rating and issued a $15.00 price target on shares of Bicycle Therapeutics in a research note on Wednesday, January 22nd. HC Wainwright reissued a "buy" rating and issued a $33.00 price objective on shares of Bicycle Therapeutics in a research report on Wednesday, February 26th. B. Riley reduced their target price on shares of Bicycle Therapeutics from $28.00 to $17.00 and set a "neutral" rating for the company in a report on Friday, December 13th. JMP Securities decreased their price target on shares of Bicycle Therapeutics from $32.00 to $26.00 and set a "market outperform" rating on the stock in a research note on Wednesday, December 18th. Finally, Needham & Company LLC restated a "buy" rating and set a $30.00 price objective on shares of Bicycle Therapeutics in a research report on Tuesday, March 11th.

Insiders Place Their Bets

In other Bicycle Therapeutics news, CAO Travis Alvin Thompson sold 2,686 shares of the stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $15.00, for a total transaction of $40,290.00. Following the sale, the chief accounting officer now directly owns 32,146 shares in the company, valued at $482,190. This represents a 7.71 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Santiago Arroyo sold 4,943 shares of the firm's stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $14.09, for a total transaction of $69,646.87. Following the completion of the transaction, the insider now directly owns 69,057 shares in the company, valued at approximately $973,013.13. This represents a 6.68 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 27,677 shares of company stock worth $392,413 in the last quarter. Corporate insiders own 8.50% of the company's stock.

Remove Ads

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in BCYC. Barclays PLC lifted its stake in Bicycle Therapeutics by 878.3% during the fourth quarter. Barclays PLC now owns 2,612 shares of the company's stock worth $37,000 after purchasing an additional 2,345 shares during the last quarter. Avior Wealth Management LLC acquired a new stake in shares of Bicycle Therapeutics in the 4th quarter valued at approximately $57,000. China Universal Asset Management Co. Ltd. grew its holdings in shares of Bicycle Therapeutics by 30.7% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 9,329 shares of the company's stock valued at $131,000 after purchasing an additional 2,191 shares during the last quarter. JPMorgan Chase & Co. increased its position in Bicycle Therapeutics by 26.8% during the 3rd quarter. JPMorgan Chase & Co. now owns 8,424 shares of the company's stock worth $191,000 after purchasing an additional 1,782 shares in the last quarter. Finally, Erste Asset Management GmbH bought a new position in Bicycle Therapeutics in the 3rd quarter valued at approximately $325,000. 86.15% of the stock is owned by institutional investors.

Bicycle Therapeutics Stock Down 2.4 %

Shares of BCYC stock traded down $0.22 on Wednesday, reaching $8.97. The stock had a trading volume of 278,673 shares, compared to its average volume of 395,137. Bicycle Therapeutics has a 12 month low of $8.60 and a 12 month high of $28.67. The firm has a market capitalization of $620.74 million, a price-to-earnings ratio of -2.73 and a beta of 1.12. The firm's 50-day moving average is $11.32 and its two-hundred day moving average is $17.52.

Bicycle Therapeutics (NASDAQ:BCYC - Get Free Report) last released its quarterly earnings data on Tuesday, February 25th. The company reported ($0.75) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.85) by $0.10. Bicycle Therapeutics had a negative return on equity of 27.35% and a negative net margin of 450.64%. The firm had revenue of $3.70 million for the quarter, compared to analyst estimates of $5.47 million. During the same quarter in the prior year, the company earned ($1.16) earnings per share. The business's revenue for the quarter was down 30.2% compared to the same quarter last year. On average, sell-side analysts forecast that Bicycle Therapeutics will post -3.06 earnings per share for the current fiscal year.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.